Notably, the exhaustion marker TIM3 displayed a significantly higher expression in AML‐CTLs than control‐CTLs (FDR < 0.05), whereas no significant difference was detected in the expression of other molecules, including PD‐1 and CTLA‐4 that represent targets of approved drugs used for specific cancer patient groups. This evidence concerns the gene CTLA4 and acute myeloid leukemia.